Introduction: As vaccine development was initiated almost immediately after the pandemic started, current major vaccines, including BNT162b2, mRNA1273 and ChAdOx1-S, are all based on the original strain without D614G.
Introduction: One of the salient mutations, spike-D614G, appeared in January 2020 and soon became ubiquitously dominant by April.
COVID-19 outbreak in Malaysia: Decoding D614G mutation of SARS-CoV-2 virus isolated from an asymptomatic case in Pahang.
PMID: 35377633
2022
Journal of chemical information and modeling
Abstract: In this study, we employed efficient and accurate coarse-grained simulations of multiple structural substates of the D614G spike trimers together with the ensemble-based mutational frustration analysis to characterize the dynamics signatures of the conformational landscapes.
Abstract: The recent structural and biophysical studies provided important evidence about multiple conformational substates of the D614G spike protein.
Abstract: The results suggest that the D614G mutant may employ a hinge-shift mechanism in which the dynamic couplings between the site of mutation and the interprotomer hinge modulate the interdomain interactions, global mobility change, and the increased stability of the open form.
Abstract: The structural and functional studies of the SARS-CoV-2
The basis of mink susceptibility to SARS-CoV-2 infection.
Abstract: Based on previous reports and our observations, we can conclude that the occurrence of one of two mutations
Figure: Abbreviations stand for: CT, cytoplasmic domain; D614G, mutation in the S protein; F486L, mutation in the S protein; FP, fusion peptide; HR1, heptapeptide repeat sequence 1; HR2, heptapeptide repeat sequence 2; N501T, mutation in the S protein; NDT, N-terminal domain; PRRA, polybasic cleavage site; RBD, receptor-binding domain; S1, S1 subunit of the S protein; S2, S2 subunit of the S protein; TM, transmembrane domain; Y453F, mutation in the S protein.
Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage.
Method: A subset of eleven of these samples were used to test neutralization activity against Delta (N = 11) and C.1.2 (N = 11) using the pseudovirus neutralization assay and ADCC (N = 9) activity against D614G and C.1.2.
Method: ChAdOx1 nCOV-19 (AZD1222) Vaccinees: samples from donors vaccinated with the ChAdOx1 nCOV-19 (AZD1222) vaccine were previously assessed for neutralization activity against the D614G (N = 11) and Beta variants (N = 11).
Method: HEK293T cells were transfected with 5 mug of SARS-CoV-2 wild-type variant spike (D614G), Beta, Delta or C.1.2 spike plasmids using PEI-MAX 40,000 (Polysciences) and incubated for 2 days at 37C.
Method: Janssen/Johnson and Johnson (Ad26.COV2.S) Vaccinees: samples from healthy donors vaccinated with the Janssen/Johnson and
COVID-19 outbreak in Malaysia: Decoding D614G mutation of SARS-CoV-2 virus isolated from an asymptomatic case in Pahang.
Result: All SARS-CoV-2 S saRNA-vaccinated hamsters showed serum neutralizing antibody levels against D614G virus similar to or higher than those in two human convalescent sera collected more than 3 weeks after recovery from first wave infection whereas there was no S specific IgG nor neutralizing activity detected in pre immunization sera (not shown) or in sera from influenza HA vaccinated hamsters.
Result: For a subset of hamsters (7/12), there was sufficient serum volume to re-test the neutralizing activity against the Alpha VOC, and titres against this variant were not significantly different than against the D614G virus (Fig S1a).
Result: Six hamsters received 103 PFU of a D614G isolate from UK collected in summer 2020, B.1.238, and six received 103 P
Table: D614G
Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020.
Discussion: Subsequently, in the month of February the D614G mutant entered in North Italy rapidly spreading to the rest of Italy and Europe, determining a different epidemiological profile of the Italian epidemic since then sustained only by B.1 lineage and his descendants.
Discussion: The introduction in Italy of the D614G variant with a greater transmissibility and its hidden circulation for weeks before the detection of the first cases in Italy could be responsible for the rapid spread of the epidemic in Northern Italy followed by spread to other Italian regions and possibly to the rest of Europe, similar to what was observed for lineage B.1.7.7, firstly predominating in UK and, subsequently, in many other European (and extra-European) countries (eCDC, rapid risk assessment, 15 February 2021).
Discussion: The second phylogeographic scenario involving lineage B.1, showed initially only a few introductions from As
SARS-CoV-2 Mutations and COVID-19 Clinical Outcome: Mutation Global Frequency Dynamics and Structural Modulation Hold the Key.
PMID: 35386683
2022
Frontiers in cellular and infection microbiology
Result: On the other hand, among the rest of the mutations in the mortality group that did not exhibit any frequency flip (24 mutations), we observed five mutations (C241T, F924F, P4715L, D614G, Q75H) with a high cohort and global distribution.
Discussion: A study by also demonstrated the mutations C241T, F924F, and P4715L to
Discussion: Furthermore, they also found that the loss of orf3b coincides with the emergence of D614G spike mutation that strikingly correlates with our observation of D614G being present at high frequency in our mortality patients.
SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies.
PMID: 35380448
2022
Science translational medicine
Abstract: A booster vaccination increased titers more than 30-fold against Omicron to values comparable to those seen against the D614G variant after two immunizations.
Abstract: Of these, only three retained potencies comparable to the D614G variant.
Figure: (A to C) Neutralization curves against D614G (black) and Omicron (red) are shown for eleven monoclonal neutralizing antibodies (nAb) and one tri-specific antibody mimetic protein (DARPin) (A), five cocktail neutralizing antibody products (B), and two polyclonal antibody preparations (C).
Figure: (A) Neutralization assays used lentiviral pseudoviruses bearing SARS-CoV-2 spike proteins from D614G, Delta, or Omicron.
Figure: (D) IC50 values against D614G and Omicron are shown for all therapeutic antibodies
Atorvastatin Effectively Inhibits Ancestral and Two Emerging Variants of SARS-CoV-2 in vitro.
Discussion: Consistent with this report, our data showed that ATV also inhibited D614G strain in Caco-2 (EC50 = 7.4 muM), a colorectal epithelial cell line highly permissive for SARS-CoV-2 infection.
Discussion: In the present study, the antiviral effect of atorvastatin against SARS-CoV-2 D614G strain was identified by the treatment of Vero E6 cells at different times of infection.
Discussion: In this study, Vero E6 cells were treated with ATV for 48 h after infection, obtaining a reduction of the infectious SARS-CoV-2 D614G particles at all evaluated concentrations.
Discussion: Similar to this report, our study demonstrated that ATV inhibited D614G strain at 31.2 muM by pretreating cells for 1 h.
Discussion: The results presented in this article also showed a reduction of the intracell
Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant.
Abstract: Mutational analysis detected 18,261 mutations in the omicron variant, majority of which were non-synonymous mutations in spike (A67, T547K, D614G, H655Y, N679K, P681H, D796Y, N856K, Q954H), followed by RNA dependent RNA polymerase (rdrp) (A1892T, I189V, P314L, K38R, T492I, V57V), ORF6 (M19M) and
ViMRT
SARS_CoV_2 mutation literature information.
PMID: 
2022
Future microbiology
